Treatment of multidrug-resistant tuberculosis during pregnancy: A report of 7 cases

Clinical Infectious Diseases

Volumn 36, Issue 8, 2003, Pages 996-1003

  Shin, Sonya ^a,b   Guerra, Dalia ^c   Rich, Michael ^a,b   Seung, Kwonjune J ^a   Mukherjee, Joia ^a,b   Joseph, Keith ^a,b   Hurtado, Rocio ^a   Alcantara, Felix ^c   Bayona, Jaime ^c   Bonilla, Cesar ^d   Farmer, Paul ^a,b   Furin, Jennifer ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SOCIOS EN SALUD   (Peru)

^d MINISTERIO DE SALUD   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONGENITAL HEART DISEASE; DOWN SYNDROME; DRUG SAFETY; EAR MALFORMATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOKALEMIA; INFECTION RISK; INTESTINE ATRESIA; LIMB DEFECT; LUNG INJURY; MULTIDRUG RESISTANCE; MUSCULOSKELETAL DISEASE; OTOTOXICITY; OUTCOMES RESEARCH; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SKIN DISCOLORATION; SPINA BIFIDA; TERATOGENICITY; TREATMENT FAILURE; TREATMENT PLANNING; TUBERCULOSIS; VERTICAL TRANSMISSION; CASE REPORT; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0037447371     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374225     Document Type: Article

References (80)

1. Pablos-Mendez A, Raviglione M, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338:1641-9.
2. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784-91.
3. Schaefer G, Zervoudakis IA, Fuchs FF, David S. Pregnancy and pulmonary tuberculosis. Obstet Gynecol 1975; 46:706-15.
4. Miller KS, Miller JM. Tuberculosis in pregnancy: interactions, diagnosis, and management. Clin Obstet Gynecol 1996; 39:120-42.
5. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119-28.
6. Farmer PE, Furin JJ, Shin SS. Managing multidrug-resistant tuberculosis. J Respir Dis 2000; 21:53-6.
7. Warkany, J. Antituberculous drugs. Teratology, 1979; 20:133-8.
8. Good JT, Iseman MD, Davidson PT, Lakshminarayan S, Sahn SA. Tuberculosis in association with pregnancy. Am J Obstet Gynecol 1981; 140:492-8.
9. Scheinhorn DJ, Angelillo VA. Antituberculous therapy in pregnancy: risks to the fetus. West J Med 1977; 127:195-8.
10. Anderson GD. Tuberculosis in pregnancy. Semin Perinatol 1997; 21:328-35.
11. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-48.
12. Hamadeh MA, Glassroth J. Tuberculosis and pregnancy. Chest 1992; 101:1114-20.
13. Vallejo JG, Starke JR. Tuberculosis and pregnancy. Clin Chest Med 1992; 13:693-707.
14. Robinson CA, Rose NC. Tuberculosis: current implications and management in obstetrics. Obstet Gynecol Surv 1996; 51:115-24.
15. Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Saf 1995; 12:1-25.
16. Starke JR. Tuberculosis: an old disease but a new threat to the mother, fetus, and neonate. Clin Perinatol 1997; 24:107-27.
17. Figueroa-Damaian R, Arredondo-Garcia JL. Pregnancy and tuberculosis: influence of treatment on perinatal outcome. Am J Perinatol 1998; 15:303-6.
18. Myers JP, Perlstein PH, Light IJ, Towbin RB, Dincsoy HP, Dincsoy MY. Tuberculosis in pregnancy with fatal congenital infection. Pediatrics 1981; 67:89-94.
19. Cantwell MF, Shehab ZM, Costello AM, et al. Brief report: congenital tuberculosis. N Engl J Med 1994;330:1051-4.
20. Hageman JR. Congenital and perinatal tuberculosis: discussion of difficult issues in diagnosis and management. J Perinatol 1998; 18:389-94.
21. Nitta A, Milligan D. Management of four pregnant women with multidrug-resistant tuberculosis. Clin Infect Dis 1999; 28:1298-304.
22. Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24:553-65.
23. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
24. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol 2000; 5:3-22.
25. United States Pharmacopeia (USP). Capreomycin. In: USP DI. Vol 1. Drug information for the health care professional. 14th ed. Rockville, MD: Pharmacopial Convention, 1994:708.
26. Gabrovska DS, Rusev GK. Antibiotic action on the embryonic development of the fetuses of amphibians. Eksp Med Morfol 1978; 17:54-9.
27. Kropp R, Jungbluth H, Radenbach K. Influence of capreomycin on renal function (preliminary results). Antibiot Chemother 1970; 16:59-68.
28. Garfield J, Jones J, Cohen N, Daly J, McClement J. The auditory, vestibular and renal effects of capreomycin in humans. Ann NY Acad Sci 1966; 135:1039-46.
29. Fujimori H, Yamada F, Shibukawa N, et al. The effect of tuberculostatics on the fetus: an experimental production of congenital anomaly in rats by ethionamide. Proc Congenital Anomalies Research Assoc Japan 1965; 5:34-5.
30. Dluzniewski A, Gastol-Lewinska L. The search for teratogenic activity of some tuberculostatic drugs. Dissertationes Pharmaceuticase et Pharmacologicae 1971; 23:383-92.
31. Khan I, Azam A. Study of teratogenic activity of trifluoperazine, amitriptyline, ethionamide, and thalidomide in pregnant rabbits and mice. Proc Eur Soc Study Drug Toxicity 1969; 10:235-42.
32. Bignall JR. Study of possible teratogenic effects of ethionamide. Bull Int Union Tuberc 1965;36:53.
33. Jentgens M. Ethionamide and teratogenic effect. Prax Pneumol 1968; 22:699-704.
34. Zierski M. Influence of ethionamide on development of human fetus. Grazlica I Choroby Plac 1966; 34:349-52.
35. Potworowski M, Sianozecka E, Szufladowicz R. Ethionamide treatment and pregnancy. Pol Med J 1966; 5:1152-8.
36. Schardein JL. Chemically induced birth defects. New York: Marcel Dekker, 1993:370.
37. Peloquin CA. Pharmacological issues in treatment of tuberculosis. Ann NY Acad Sci 2001; 953:157-64.
38. Weinstein L, Murphy T. The management of tuberculosis during pregnancy. Clin Perinatol 1974; 1:395-405.
39. Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax 2001; 56:494-9.
40. Lowe CR. Congenital defects among children born to women under supervision or treatment for pulmonary tuberculosis. Br J Prev Soc Med 1964; 18:14-6.
41. Marcus JC. Non-teratogenicity of antituberculous drugs. S Afr Med J 1967; 41:758-9.
42. Wilson EA, Thelin TJ, Ditts PV. Tuberculosis complicated by pregnancy. Am J Obstet Gynecol 1973; 115:526-9.
43. Varpela E. On the effect exerted by first-line tuberculosis medicines on the foetus. Acta Tuberc Scand 1964; 35:53-69.
44. Heinonen O, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Kaufman D, ed. Littleton, MA: Publishing Sciences Group, 1977.
45. Jotti D, Corato P, Cattini GC. Antitubercular therapy in pregnancy in relation to possible injurious effects on gestation and the fetus. Arch Maragliano Patol Clin 1968; 24:335-45.
46. Sanguigno N. Considerations on ten years' use of cycloserine. Scand J Respir Dis Suppl 1970; 71:178-9.
47. Cukieski M, Prahalada S, Zacchei A, et al. Embryotoxicity studies of norfloxacin in cynomolgus monkeys: I. Teratology studies and norfloxacin plasma concentration in pregnant and nonpregnant monkeys. Teratology 1989; 39:39-52.
48. Takayama S, Watanabe T, Akiyama Y, et al. Reproductive toxicity of ofloxacin. Arzneimittelforschung 1986; 36:1244-8.
49. Wilton L, Pearce G, Mann R. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin, and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41:277-84.
50. Schaefer C, Amoura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 1996; 69:83-9.
51. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 84:535-8.
52. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrobial Agents Chemother 1998; 42:1336-9.
53. Stenger E, Aeppli L, Pehem E, Thomann PE. A contribution to the toxicology of the leprostatic drug, 3-p-(chloroanilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)- phenazine (G 30320). Acute and subacute toxicity, reproduction toxicology. Arzneimittelforschung 1970; 20:794-9.
54. Farb H, West D, Pedvis-Leftick A. Clofazimine in pregnancy complicated by leprosy. Obstet Gynecol 1982; 59:122-3.
55. Holdiness M. Clofazimine in pregnancy. Early Human Development 1989; 18:297-8.
56. Product information: Biaxin, Abbott Laboratories, 1998.
57. Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998; 15:523-5.
58. Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Safety 2000; 9:549-56.
59. Korzeniowski O. Antibacterial agents in pregnancy. Infect Dis Clin North Am 1995; 9:639-51.
60. Pedler SJ, Bint AJ. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother 1985; 27:508-10.
61. Holdiness MR. Clinical pharmacokinetics of antituberculosis drugs. Clin Pharmacokinet 1984; 9:511-44.
62. Snider DE, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med 1984; 144:589-90.
63. Tran JH, Montakantikul P. The safety of antituberculosis medications during breastfeeding. J Hum Lact 1998; 14:337-40.
64. Brost BC, Newman RB. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am 1997; 24:659-73.
65. Snider DE, Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122:65-79.
66. Monnet P, Kalb JC, Pujol M. Must one fear the teratogenic influence of isoniazid? [in French]. Rev Tuberc Pneumol (Paris) 1967; 31:845-8.
67. Levene CI, Carrington MJ. The inhibition of protein-lysine 6-oxidase by various lathyrogens: evidence for two different mechanisms. Biochem J 1985; 232:293-6.
68. McKenzie SA, Macnab AJ, Katz G. Neonatal pyridoxine responsive convulsions due to isoniazid therapy. Arch Dis Child 1976; 51:567-8.
69. Burka ER, Weaver Z, Marks P. Clinical spectrum of hemolytic anaemia associated with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1966; 64:817-25.
70. Steen JSM, Stainton-Ellis DM. Rifampicin in pregnancy. Lancet 1977;2:604-5.
71. Bobrowitz ID. Ethambutol in pregnancy. Chest 1974; 66:20-4.
72. Lewit T, Nebel L, Terracina S. Ethambutol in pregnancy: observation on embryogenics. Chest 1974; 66:25-6.
73. Varpela E, Hietalahti J, Aro M. Streptomycin and dihydrostreptomycin medication during pregnancy and their effect on the child's inner ear. Scand J Respir Dis 1969; 50:101-9.
74. Varpela E, Hietalahti J. Streptomycin medication during pregnancy and the child's hearing. Ann Paediatr Fenn 1965; 11:38-46.
75. Ganguin G, Rempt E. Streptomycin therapy during pregnancy and its effect on the hearing of the offspring. Z Laryngol Rhinol Otol 1970; 49:496-503.
76. Conway N, Bird S. Streptomycin in pregnancy: effect on the foetal ear. BMJ 1965; 2:260-3.
77. Robinson GC, Cambon KG. Hearing loss in infants of tuberculous mothers treated with streptomycin in pregnancy. N Engl J Med 1964; 271:949-51.
78. Anson B, Bast TH. Developmental anatomy of the ear. In: Shambaugh GE. Surgery of the ear. Philadelphia: WB Saunders, 1959:3-27.
79. Nishimura H, Tanimura T. Clinical aspects of teratogenicity of drug. Amsterdam: Excerpta Medica, 1976; 131.
80. Jones HC. Intrauterine ototoxicity: a case report and review of the literature. J Natl Med Assoc 1973; 65:201-3.